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Over a 6-year period, Burkholderia cepacia complex species were isolated from cystic fibrosis (CF) patients
receiving care at The University of North Carolina Hospitals (clinic CF patients) and from those referred from
other treatment centers. Fifty-six isolates collected from 30 referred patients and 26 clinic CF patients were
characterized by pulsed-field gel electrophoresis (PFGE) and were assayed by PCR to detect the cable pilin
gene, cblA. PFGE results indicated that six separate clusters (clusters A to F) were present among the 56
isolates and that three clusters (clusters A, B, and E) consisted only of isolates from referred patients infected
with B. cepacia complex isolates prior to referral. However, one cluster (cluster C) consisted of isolates from
four CF patients, and hospital records indicate that this cluster began with an isolate that came from a referred
patient and that spread to three clinic CF patients. Cluster D consisted of two isolates from clinic CF patients,
and hospitalization records are consistent with nosocomial, patient-to-patient spread. cblA was present in only
4 of the 56 isolates and included isolates in cluster E from the referred patients. Our results indicate a lack
of spread of a previously characterized, transmissible clone from referred patients to our clinic CF population.
Only two instances of nosocomial, patient-to-patient spread could be documented over the 6-year period. An
additional spread of an isolate (cluster F) from a referred patient to a clinic patient could not be documented
as nosocomial and may have been the result of spread in a nonhospitalized setting. The majority (36 of 56) of
our B. cepacia complex-infected CF patients harbor isolates with unique genotypes, indicating that a diversity
of sources account for infection. These data suggest that CF patients infected with B. cepacia complex and
referred for lung transplantation evaluation were not a major source of B. cepacia complex strains that infected
our resident CF clinic population.
The Burkholderia cepacia complex is composed of at least
seven closely related species or genomovars consisting of B.
cepacia (genomovar I), B. multivorans (genomovar II), B. sta-
bilis (genomovar IV), B. vietnamiensis (genomovar V), and B.
ambifaria (genomovar VII), and genomovars III and VI, with
species designations for genomovars III and VI still pending
(4, 8).
Nearly 4% of cystic fibrosis (CF) patients in the United
States are infected with a member of the B. cepacia complex
(13). Of these patients, some will develop the cepacia syn-
drome, a rapidly fatal necrotizing pneumonia with bacteremia
(9, 10, 26). Previous studies have shown that transmissible
clones of B. cepacia exist, and subsequent infection with these
clones of both healthy uninfected CF patients and CF patients
seeking lung transplantation can be devastating (9, 11, 12, 22,
25). Therefore, screening of CF patients for the detection of B.
cepacia complex and management of patients once infection is
documented are extremely important. Furthermore, CF pa-
tients infected with B. cepacia complex isolates are stigmatized,
being segregated from the general CF patient population in
terms of clinical care and social interaction. In many North
American transplant centers, infection with B. cepacia complex
is a strict contraindication for lung transplantation in CF pa-
tients (14).
There are more than 120 lung transplantation centers in
North America. The University of North Carolina (UNC) Hos-
pitals is one of the few CF centers in North America that will
perform lung transplantation for CF patients infected with B.
cepacia complex. For this reason, about 14% of adult CF pa-
tients (i.e., roughly three times the national percentage) re-
ferred to the UNC Hospitals for double lung transplantation
are infected with B. cepacia complex.
Some transmissible clones of B. cepacia complex exist, such
as the cable pilin-positive (cblA) electropherotype (ET) ET
12 clone responsible for epidemic transmission in both Canada
and the United Kingdom (7, 9, 11, 21, 22, 25). Therefore, we
believed that it was important to study the CF patient popu-
lation at the UNC Hospitals by asking three questions. First,
have referred patients brought a previously characterized,
transmissible clone into our (the UNC Hospitals) center, and
has it been transmitted to our clinic CF patient population?
Second, are any new, previously uncharacterized, transmissible
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clones evident among our referred patients, and has transmis-
sion from referred patients to our local clinic CF population
occurred? Third, how much intracenter spread of B. cepacia
complex has occurred?
MATERIALS AND METHODS
Characterization of UNC Hospitals CF center and infection control. All B.
cepacia complex isolates were recovered from CF patients between 1 January
1995 and 1 March 2001. We studied two distinct patient populations from which
B. cepacia complex organisms were isolated. One consisted of 30 CF patients who
were referred to the UNC Hospitals, often for lung transplantation evaluation,
already infected with B. cepacia complex. The second population was of 26 CF
patients who received their routine care at the UNC Hospitals and who became
newly infected during a study period from 1 January 1997 to March 2001. For
these patients to be considered “newly infected,” prior cultures of samples from
these patients at our institution had to be negative for B. cepacia and the
organism had to be isolated during the study period.For the year 2000, 451 CF
patients received care at the UNC Hospitals, with 251 of these patients being
pediatric patients, while 200 were adult patients. Nineteen (9.5%) of the 200
adult patients and 8 (3.2%) of the 251 pediatric patients were infected with B.
cepacia complex. A total of 107 CF patients are awaiting lung transplantation at
the UNC Hospitals, with 15 (14%) of these patients infected with B. cepacia
complex. As part of the evaluation of possible nosocomial transmission among
CF patients whose isolates were in clusters C, D, and F, all patient charts were
reviewed by a nurse trained in infection control. The review included production
of a time line of all hospital admissions including hospital location, clinic visits,
physical and occupational therapy visits, pulmonary rehabilitation visits, and
evaluations in specialty clinics (e.g., pulmonary function laboratory, radiology,
and transplantation clinics). Patients with known B. cepacia complex colonization
requiring inpatient hospitalization were admitted to private rooms and placed on
contact precautions. When pediatric patients with B. cepacia complex were seen
in the outpatient clinic, they either were scheduled to be seen on a different day
than other CF patients or were scheduled to be seen at the end of the day, after
all patients not infected or colonized with B. cepacia had left the facility. Until
1998, adult CF patients were seen in the general pulmonary clinics in order to
minimize contact with each other. In 1998, the formation of a dedicated adult CF
clinic prompted the institution of several infection control measures, including
patient education, masking of all patients upon arrival at the clinic and in all
common areas, strict adherence to hand-washing procedures, and disinfection of
rooms between patients. The UNC Hospitals Lung Transplant Clinic adopted
similar infection control guidelines in 2000.
B. cepacia isolation, PFGE, and cblA analysis. All strains were isolated on
either Pseudomonas cepacia agar or B. cepacia selective agar prepared in-house
and were further characterized biochemically and by PCR genomovar analysis as
described previously (6, 16, 19). Once a member of the B. cepacia complex was
isolated from a CF patient, a subculture was prepared from a single colony and
stocks were prepared in skim milk and frozen at 70°C.
Pulsed-field gel electrophoresis (PFGE) was conducted as described previ-
ously, with the following revisions (7). All cultures were grown overnight in
tryptic soy broth and adjusted to an optical density at 600 nm of 1. One milliliter
was removed and centrifuged for 5 min to pellet the cells. The cells were then
resuspended in formalin (3.8% [vol/vol]) (5) and allowed to sit on ice for 1 h. The
cells were pelleted and rinsed three times in TE (10 mM Tris-HCl, 10 mM EDTA
[pH 8.0]) before being placed in agarose blocks. Genomic DNA was restricted
with SpeI (New England Biolabs); and electrophoresis was conducted for 24 h in
0.5 TBE (Tris-borate, EDTA), with initial and final pulse times of 1.2 and 54 s,
respectively, by using a CHEF Mapper system (Bio-Rad). An ET 12 strain of B.
cepacia complex was kindly provided by R. Goldstein, Boston University School
of Medicine (25). Gels were analyzed visually according to the criteria of
Tenover et al. (27).
All isolates of B. cepacia complex were tested by PCR for the presence of the
cable pilin gene, cblA, as described previously (22).
RESULTS
Fifty-six B. cepacia complex isolates cultured from 56 CF
patients were characterized for their PFGE patterns (geno-
types) after digestion with SpeI (Table 1). Genotypes were
considered related if they differed by three or fewer bands (27).
In total, 42 distinct genotypes were present, which likely indi-
cates a wide diversity in the sources of infection. There were 26
genomovar II (B. multivorans) isolates, 25 genomovar III iso-
lates, two genomovar I (B. cepacia) isolates, and three geno-
movar V (B. vietnamiensis) isolates. Our PFGE analysis re-
vealed that six clusters of PFGE patterns were present within
TABLE 1. Summary of genotypes and clusters of B. cepacia complex isolates recovered from January 1995 to March 2001
Genotype Patient no. Genomovar Cluster Area cblAa
1 1 III A Michigan Neg
1 2 III A Michigan Neg
1 3 III A Michigan Neg
1a 4 III A Michigan Neg
1 5 III A Nebraska Neg
1b 6 III A Michigan Neg
2 7 III B New York Neg
2 8 III B New York Neg
2 9 III B New York Neg
2 10 III B New Jersey Neg
3 11 B. multivorans (II) C Florida Neg
3 12 B. multivorans (II) C UNC Hospitals Neg
3 13 B. multivorans (II) C UNC Hospitals Neg
3 14 B. multivorans (II) C UNC Hospitals Neg
4 15 III D UNC Hospitals Neg
4 16 III D UNC Hospitals Neg
5 17 III E Nova Scotia Pos
5 18 III E Nova Scotia Pos
6 19 III F UNC Hospitals Neg
6 20 III F New Jersey Neg
7 21 III Distinct genotype Pos
8 22 B. cepacia (I) Distinct genotype Pos
9–30 23–44 B. multivorans (II) Distinct genotypes Neg
31–38 45–52 III Distinct genotypes Neg
39–41 53–55 B. vietnamiensis (V) Distinct genotypes Neg
42 56 B. cepacia (I) Distinct genotype Neg
a Neg, negative; Pos, positive.
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the CF population at the UNC Hospitals during this study
period (Fig. 1). Three clusters consisted of strains from mul-
tiple patients (clusters A to C), while clusters D to F consisted
of isolates from only two patients each. The cluster A genotype
occurred in six patients, five of whom had previously been seen
at CF centers in Michigan and who were infected prior to care
at the UNC Hospitals. The fifth patient whose isolate was in
this cluster was also infected with B. cepacia prior to referral,
but the patient was originally from Nebraska and it is not
known whether there is a link between this patient and the
other patients whose isolates were in this cluster. Isolates from
patients 1 through 3 and 5 shared identical genotypes, while
isolates from patient 4 differed from those from patients 1
through 3 and 5 by two bands and isolates from patient 6
differed from those from patients 1 through 3 and 5 by three
bands. All were genomovar III isolates.
Likewise, cluster B isolates (Fig. 1) occurred in those re-
ferred patients seen previously at CF centers within the met-
ropolitan New York City-New Jersey area and infected prior to
care at the UNC Hospitals. Again, all were genomovar III
isolates, and there was no evidence of the spread of this cluster
to any of our clinic CF patients.
Interestingly, cluster C (Fig. 1) began with patient 11 from
Florida, who sought care at the UNC Hospitals for a possible
double lung transplantation and who was already infected with
B. multivorans. This patient had a lengthy hospitalization from
7 June 1998 until 13 August 1998 and again from 21 August
1998 until 13 March 1999 (Fig. 2). Patient 12 was also hospi-
talized from 5 through 11 August 1998, during the hospitaliza-
tion of patient 11, and subsequently became culture positive
for B. multivorans on 5 November 1998. On the same date,
patient 12 was also seen in the adult CF clinic. Patient 13 was
a pediatric patient hospitalized from 29 October 1998 until 12
November 1998 and was later (11 February 1999) culture pos-
itive for B. multivorans. Patient 14 was hospitalized from 13
through 21 December 1999 and had an overlapping hospital-
ization with patient 12. Patient 14 was then culture positive for
B. multivorans on 25 May 2000. Although these patients did not
share the same hospital floor, they did share common hospital
services (physical therapy, pulmonary function laboratory, and
radiology). Since the B. multivorans isolates from all of these
patients share the same genotype and overlapping hospitaliza-
tions were evident, we conclude that nosocomial, patient-to-
patient spread occurred among these patients either directly or
indirectly.
Three small clusters (clusters D to F) (Fig. 1) consisting of
isolates from two patients each were also detected by PFGE,
and isolates in one of these clusters (cluster E) were from
siblings who were infected with B. cepacia and who had been
referred to the UNC Hospitals (Fig. 1). As with cluster C
isolates, the isolates in cluster D were from two patients who
also had overlapping hospitalizations on the same hospital unit
that were clearly documented (data not shown). These two
patients represent part of the UNC Hospitals CF clinic popu-
lation. The isolates in cluster F consisted of isolates from
patient 19, who became infected while receiving care at the
UNC Hospitals, and patient 20, who was from New Jersey and
who came to the UNC Hospitals already infected with B.
cepacia genomovar III. We could find no evidence of overlap-
ping hospitalizations or shared hospital services between these
two patients. Therefore, we suspect that patient 19 may have
FIG. 1. PFGE banding patterns of six clusters (clusters A to F) of B. cepacia complex isolates recovered from CF patients at the UNC Hospitals
CF center. The cluster C gel contains a B. multivorans strain designated 23 for purposes of comparison. The cluster E gel contains the Toronto
strain, designated ET, and a cblA genomovar III strain, designated 21, for the purposes of comparison. Numbers on the left are molecular weights.
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become infected with an isolate of the same genotype as that
from patient 20 in a nonhospitalized setting (23).
Epidemic clone ET 12, isolated from CF centers in both the
United Kingdom and North America, expresses cable pilin on
its surface (25). For this reason, we performed PCR on our
isolates to see if the cblA gene was present, especially in our
cluster isolates. Our results show that the cblA gene was
present in only four isolates, two of which were from cluster E
(isolates from a sibling pair). A comparison of the SpeI restric-
tion patterns between the B. cepacia cblA isolates from the
siblings (patients 17 and 18) and patient 21 with that of the
highly transmissible Toronto strain is shown in Fig. 1. The
results indicate that while the SpeI patterns for the isolates
from the siblings are an exact match, the genotypes produced
by isolates from the siblings, patient 21, and the ET 12 clone
differ from each other by more than seven fragments and are
therefore unrelated (25). A fourth patient infected with a
cblA strain also showed a unique SpeI genotype, as expected,
since this isolate was a genomovar I strain (data not shown),
while the other cblA isolates were genomovar III strains (Ta-
ble 1).
DISCUSSION
In an earlier study, we analyzed B. cepacia complex isolates
from five transplant patients and 17 clinic patients and found
no evidence of transmission of B. cepacia complex isolates
among these patients (24). However, we did find a strain of B.
cepacia complex in a patient referred for transplantation eval-
uation that resulted in the recognition of a large nosocomial
outbreak at the institution from which he was referred (9). This
caused us to be concerned that patients referred for transplan-
tation might transmit B. cepacia complex strains to patients
receiving their routine care for CF at our institution.
Of the six clones found in clusters in this study, isolates of
four previously uncharacterized clones (clusters B, C, E, and
F) were present in our referred patients, while cluster A has
been reported previously (12) and cluster D isolates were not
present in patients referred for transplantation. Cluster B iso-
lates were present in four referred patients from the metro-
politan New York City-New Jersey area. To our knowledge,
there is no published study of an epidemic clone of the B.
cepacia complex from CF patients from that geographic area.
Therefore, we cannot comment on the transmissibility of this
clone except to say that it was present in these four referred CF
patients and did not spread to our clinic CF patients.
Cluster C comprised a clone of B. multivorans. Among the
isolates in the B. cepacia complex, transmissibility is typically
thought to be associated with B. cepacia genomovar III organ-
isms (2, 7, 9, 11, 21, 22, 25). Person-to-person spread of B.
multivorans is not as frequently described, and most patients
infected with B. multivorans are infected with unique strains (1,
14). Overlapping hospitalizations could be traced for all four
patients infected with cluster C isolates. Cluster E consisted of
only two isolates from referred patients who were siblings, but
the isolates were cblA. Again, there was no evidence of
spread from these referred patients to our clinic CF patient
population. Cluster F consisted of isolates from two patients
and represented the spread of B. cepacia genomovar III from
a referred patient to a clinic CF patient. However, we were
unable to show any link between these two patients through
overlapping hospitalizations, clinic visits, or hospital services
and therefore consider this cluster not to have occurred noso-
comially.
A closer analysis of the isolates in cluster A indicated that
four of five referred patients from Michigan were infected with
isolates with identical genotypes (cluster A) when they arrived
at the UNC Hospitals and that the isolate from the fifth patient
(Fig. 1, patient 4) possessed a genotype that differed from that
of the isolates from the first four patients by only two bands.
Digestion with XbaI and PFGE of the isolate from patient 4
allowed us to confirm by direct comparison with the PFGE
results of Kumar et al. (12) that these isolates were part of the
cluster of genetically related isolates from five CF centers in
Michigan (data not shown). We were initially alarmed at find-
ing this cluster among our referred patients. However, we
found no evidence of the spread of isolates in this cluster to any
of the other CF patients screened in this study. Cluster A also
included an isolate from a single referred patient from Ne-
braska. We have not been able to verify whether this patient
FIG. 2. Time line graph showing the hospitalization course of patients (Pt.) 11 to 14. Horizontal bars represent inpatient status, with the
admission date given at the beginning of the bars and the discharge date given at the ends. Vertical bars represent dates of concurrent admission
resulting in possible cross infection. #, , and , the dates that patients 12, 13, and 14, respectively, first became positive for B. multivorans infection
(see text).
VOL. 40, 2002 MOLECULAR ANALYSIS OF B. CEPACIA COMPLEX 1191
attended some of the same CF camps or CF centers as the rest
of the patients whose isolates were in cluster A.
One of the shortcomings of our study design was that we
studied only a single isolate from each patient. We had two
instances in which isolates from sibling pairs had different
genotypes. Patient 14 is a sibling of patient 23, and both pa-
tients were infected with the same genomovar (B. multivorans)
but the genotypes of the isolates were not related. In another
instance, we noted that isolates from siblings (patient 10,
whose isolate was in cluster B, and patient 20, whose isolate
was in cluster F) differed in their genotypic patterns. Since we
studied only one isolate from each patient, it is possible that
the siblings may have been infected with isolates with common
genotypes that were not detected. We previously showed that
over time patients harbor B. cepacia complex isolates with the
same genotype (24).
Overall, the results of our genotype analysis indicate that the
spread of a previously characterized, transmissible clone of B.
cepacia from referred patients to our clinic CF patient popu-
lation has not occurred. Other studies have indicated that a
high percentage of patients at CF centers often harbor en-
demic, transmissible clones (2, 12, 15, 17, 23, 25, 29). In con-
trast, our PFGE results did not indicate the presence of a
common, transmissible clone among our clinic CF patient pop-
ulation. Our results more closely parallel those of a recent
study (20) indicating that hospitals with a segregation policy
tend to have patients infected with unique strains. Docu-
mented nosocomial spread involved 4 of 26 (15%) of our clinic
B. cepacia complex-infected patients (patients 12 to 14, whose
isolates were in cluster C, and patient 16, whose isolate was in
cluster D).
A recent publication indicated that in the United Kingdom
the cblA gene may be used as a marker to identify strains with
an enhanced capacity for spread (3). We found the cblA gene
in only 4 of the 56 B. cepacia isolates that we examined. Two of
the four isolates were from referred siblings from Canada and
were in cluster E. However, the genotype for cluster E isolates
differed from that of the epidemic, cblA ET 12 strain, also
isolated from Canadian patients, by more than seven frag-
ments, and they are therefore considered genetically unre-
lated. There was no evidence of spread of cblA clones in our
patient population. Our data are consistent with those of
LiPuma and colleagues (18), who found that only 1 of 606
isolates carried the cblA gene. These data suggest that other
factors are important in the transmissibility of the genomovar
III organisms.
The most frequently recovered B. cepacia complex species
from CF patients are genomovar III (18), and recent data
indicate that CF transplant patients infected with genomovar
III suffer higher rates of mortality than those infected with
another genomovar (1). However, it is apparent from our study
and those of others that B. multivorans can also be frequently
recovered (8, 18, 28). In fact, our results indicate that B. mul-
tivorans was slightly more prevalent than genomovar III among
our CF patient population (26 and 25 patients, respectively).
Our results also revealed that 36 of the 56 CF patients seeking
care at the UNC Hospitals harbor strains with unique geno-
types, so their sources of infection are likely to be diverse.
In conclusion, our study of B. cepacia complex-infected CF
patients indicated that transmission of an isolate from a re-
ferred patient to our clinic CF patient population occurred in
only two instances (with isolates in clusters C and F), but
nosocomial transmission could clearly be documented for only
one of these isolates (a cluster C isolate). Intracenter trans-
mission of isolates in one, two-patient cluster (cluster D) oc-
curred within our clinic patient population. Our clinic patients
were infected with a variety of different genotypes of the B.
cepacia complex. These data suggest that CF patients who were
infected with B. cepacia complex isolates and who were re-
ferred for lung transplantation evaluation were not a major
source of the B. cepacia complex organisms that infected our
resident CF clinic population.
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